CureVac raises equity to fund Covid-19 vaccine rollout

GLOBALCAPITAL INTERNATIONAL LIMITED, a company

incorporated in England and Wales (company number 15236213),

having its registered office at 4 Bouverie Street, London, UK, EC4Y 8AX

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
ABBs-Block Trades

CureVac raises equity to fund Covid-19 vaccine rollout

Aidan Gregory
January 26, 2021 11:00 AM
CureVac_2_575_375
An illustrative image of medical syringes in front of CureVac and Bayer logos displayed on a screen. On Monday, January 18, 2021, in Dublin, Ireland. (Photo by Artur Widak/NurPhoto) | Artur Widak/NurPhoto/PA Images

CureVac, the German biotechnology company, has launched a $523m share sale to fund late stage clinical trials for its Covid-19 vaccine, and an expansion of its manufacturing capacity.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

GermanyHealth and BiotechEquityABBs-Block TradesEuropeEMEASRI
AG
Aidan Gregory
Gift this article